tiprankstipranks
Trending News
More News >
Alnylam Pharmaceuticals (ALNY)
NASDAQ:ALNY
US Market

Alnylam Pharma (ALNY) Ownership - Who Owns Alnylam Pharma?

Compare
1,236 Followers

Alnylam Pharma (ALNY) Ownership Overview

0.42%48.30%0.09%15.52%35.67%
0.09% Other Institutional Investors
15.52% ETFs
35.67% Public Companies and Individual Investors
The ownership structure of Alnylam Pharma (ALNY) stock is a mix of institutional, retail, and individual investors. Approximately 63.91% of the company’s stock is owned by Institutional Investors, 0.42% is owned by Insiders, and 35.67% is owned by Public Companies and Individual Investors.
The ownership structure of Alnylam Pharma (ALNY) stock is a mix of institutional, retail, and individual investors. Approximately 48.39% of the company’s stock is owned by Institutional Investors, 0.42% is owned by Insiders, and 15.52% is owned by Public Companies and Individual Investors.

Recent Insider Trading Activity

Date
Name
Activity
Value
May 12, 2025
xxxxxxxxxxxxx
$10363
May 12, 2025
xxxxxxxxxxxxx
$8383
Mar 05, 2025
xxxxxxxxxxxxx
$945165
Mar 05, 2025
xxxxxxxxxxxxx
$189183

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value
Mar 31, 2025
xxxxxxxxxxxxx
$135010
Mar 31, 2025
xxxxxxxxxxxxx
$2268168
Mar 31, 2025
xxxxxxxxxxxxx
$43082771

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
12,546,166Institution9.62%3,579,546,621
11,262,910Institution8.64%3,213,420,852
10,189,088Institution7.81%2,907,048,697
4,512,206Institution3.46%1,287,377,494
3,351,762Institution2.57%956,291,216
2,970,610Institution2.28%847,544,739
2,931,495Institution2.25%836,384,838
2,733,941Institution2.10%780,020,707
2,408,936Institution1.85%687,293,530
2,331,142Institution1.79%665,098,124

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
11,262,910Institution8.64%3,213,420,852
10,189,088Institution7.81%2,907,048,697
2,970,610Institution2.28%847,544,739
2,931,495Institution2.25%836,384,838
2,733,941Institution2.10%780,020,707
2,408,936Institution1.85%687,293,530
2,331,142Institution1.79%665,098,124
1,914,351Institution1.47%546,183,484
1,882,997Institution1.44%537,237,874
1,645,900Institution1.26%469,591,729

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
4,151,970Institution3.18%1,092,964,583
2,814,849Institution2.16%740,980,851
2,002,667Institution1.54%527,182,061
1,553,318Institution1.19%408,895,430
1,002,755Institution0.77%263,965,226
774,241Institution0.59%220,898,700
668,413Institution0.51%190,704,913
532,116Institution0.41%150,801,674
447,379Institution0.34%126,787,209
441,823Institution0.34%126,056,520

FAQ

Who Owns Alnylam Pharmaceuticals (ALNY)?
According to the latest TipRanks data, approximately 0.09% of the company's stock is held by institutional investors, 0.42% is held by insiders, and 35.67% is held by retail investors.
    What percentage of Alnylam Pharmaceuticals (ALNY) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 0.09% of Alnylam Pharmaceuticals (ALNY) stock is held by institutional investors.
      What percentage of Alnylam Pharmaceuticals (ALNY) stock is held by retail investors?
      According to the latest TipRanks data, approximately 35.67% of Alnylam Pharmaceuticals (ALNY) stock is held by retail investors.
        Who owns the most shares of Alnylam Pharmaceuticals (ALNY)?
        Vanguard owns the most shares of Alnylam Pharmaceuticals (ALNY).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis